Safety and Dystrophin Expression of SPOT-mRNA03 in Duchenne Muscular Dystrophy (DMD) Patients

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 6, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Duchenne Muscular Dystrophy (DMD)

Interventions

GENETIC

mRNA

mRNA therapy delivered by extracellular vesicles (EVs)

Trial Locations (1)

RECRUITING

Shanghai Children's Medical Center, Shanghai

All Listed Sponsors

collaborator

Shanghai Children's Medical Center

OTHER

lead

Shanghai Siponuoyin Biotechnology Co Ltd

INDUSTRY

NCT07188012 - Safety and Dystrophin Expression of SPOT-mRNA03 in Duchenne Muscular Dystrophy (DMD) Patients | Biotech Hunter | Biotech Hunter